Bupropion (Wellbutrin)

Safety Summary

Regulatory Status

Sources

These citations are the ones recorded for the human adult context.

• FDA Prescribing Information: Bupropion (Wellbutrin/Zyban/Aplenzin) — MDD/SAD/smoking cessation; seizure risk; eating disorder contraindication; NDRI mechanism; no sexual dysfunction; no weight gain; CYP2B6 metabolism; extended-release formulations; neuropsychiatric warning history (2023) REGULATORY · 2023
• ASPCA Animal Poison Control Center: Bupropion Toxicosis in Dogs — high seizure risk; extended-release delayed onset; benzodiazepine treatment; toxic dose thresholds; canine fatalities; comparison to SSRI profile; management protocol (2023) VETERINARY · 2023
• where to look PubChem: Toxicity section (CID 444) PUBCHEM
• OEHHA Proposition 65 List of Carcinogens or Reproductive Toxicants (CSV, list date 31-Jul-26) REGULATORY
• Permissible Exposure Limits – OSHA Annotated Table Z-1 REGULATORY
• where to look Hazardous Substances Data Bank (HSDB), as recorded by PubChem (Experimental Properties, CID 444; where-to-look, not a source of this value) DATABASE · 2026
• EPA CompTox CTX API: predicted properties for DTXSID7022706 (Bupropion (Wellbutrin)) REFERENCE

Same data as the API response, which is open and needs no key. The full per-record source list is available to authenticated callers.